Brad Stanfield's 2026 Study: Shocking Results!Brad Stanfield's 2026 Study: Shocking Results!
The Wellness Messiah Podcast
Rimon breaks down Dr Brad Stanfield’s rapamycin study in adults over 65, explaining why the drug appeared to blunt exercise gains and what that implies for longevity strategies. He contrasts stress‑based interventions with supportive approaches for older bodies and questions whether rapamycin is worth the risk for this age group.
19:56•30 May 2026
Rapamycin, Exercise, and Ageing Muscles: Why Brad Stanfield’s Trial Surprised Everyone
Episode Overview
- Weekly rapamycin in adults over 65 appeared to reduce or offset the benefits of a simple home exercise programme compared with placebo.
- Rapamycin acts as an anti‑growth, protein‑restriction‑like signal, which may clash with the higher protein and growth signals older adults need to maintain muscle.
- In humans, growth and recovery share pathways, so inhibiting mTOR to boost autophagy can also blunt muscle recovery after exercise.
- Older adults often have chronic inflammation and noisy signalling, making them less able to respond positively to additional stressors such as hormetic drugs.
- Rimon argues that most people over 65 benefit more from support and damage prevention than from extra stress signals, and he questions whether mild potential gains justify rapamycin’s risks and effort.
“If you're going to take a drug, especially an experimental one, it should really keep you young.”
Ever wondered what it takes to test a so‑called longevity drug in real humans rather than just mice? This conversation on The Wellness Messiah Podcast walks through exactly that, focusing on Dr Brad Stanfield’s 2026 rapamycin trial in adults aged 65 and over. Rimon, a metabolic researcher specialising in longevity, breaks down the study in plain language. Forty sedentary participants over 65 followed the same simple home exercise plan, but only half took weekly rapamycin.
The big question: “Does rapamycin help older people get more out of their exercise?” The surprise? As Rimon quotes Professor Matt Keberlein’s view, “the placebo group improved more than the rapamycin group… rapamycin attenuated the benefits of exercise.” You’ll hear Rimon unpack why a drug that extends lifespan in mice might fail – or even backfire – in older humans who are trying to build strength.
He explains rapamycin as an “anti‑growth drug”, compares it to a “protein restriction mimetic”, and highlights why that clashes with what people over 65 usually need: “Adequate protein intake… coupled with strength training” to avoid muscle loss. The episode digs into mTOR, autophagy, inflammation, and why older bodies often have “a lot of noise… chronic inflammation noise” that makes it harder to respond to extra stress signals from drugs.
Rimon also introduces his age‑based “matrix” for choosing strategies, arguing that most over‑65s need support and damage prevention more than more stress signals. This one’s aimed at people curious about longevity interventions, older adults wondering about rapamycin, and anyone in recovery or health transformation who’s been tempted by “miracle” pills. It’s a reminder that context, age, and lifestyle matter just as much as any headline‑grabbing drug.
After hearing this breakdown, are you still tempted by experimental shortcuts, or does solid exercise and support sound more appealing?
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.
Related Episodes
Similar episodes from other shows in the catalogue.